Aclaris Therapeutics Stock Price on May 29, 2024
| ACRS Stock | USD 2.73 0.19 6.51% |
Below is the normalized historical share price chart for Aclaris Therapeutics extending back to October 07, 2015. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Aclaris Therapeutics stands at 2.73, as last reported on the 29th of December, with the highest price reaching 2.97 and the lowest price hitting 2.71 during the day.
If you're considering investing in Aclaris Stock, it is important to understand the factors that can impact its price. Aclaris Therapeutics is unstable given 3 months investment horizon. Aclaris Therapeutics secures Sharpe Ratio (or Efficiency) of 0.17, which signifies that the company had a 0.17% return per unit of risk over the last 3 months. We were able to interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.85% are justified by taking the suggested risk. Use Aclaris Therapeutics Mean Deviation of 6.06, risk adjusted performance of 0.1452, and Downside Deviation of 5.85 to evaluate company specific risk that cannot be diversified away.
Aclaris Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 7th of October 2015 | 200 Day MA 1.5916 | 50 Day MA 2.7724 | Beta 0.116 |
Aclaris |
Sharpe Ratio = 0.1694
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ACRS | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.91 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.85 actual daily | 36 64% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Aclaris Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aclaris Therapeutics by adding it to a well-diversified portfolio.
Price Book 2.2448 | Enterprise Value Ebitda 0.2785 | Price Sales 10.7892 | Shares Float 55.3 M | Wall Street Target Price 10 |
Aclaris Therapeutics Main Headline on 29th of May 2024
Acquisition by Kevin Balthaser of 59000 shares of Aclaris Th... by Kevin Balthaser
Filed transaction by Aclaris Therapeutics Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Aclaris Therapeutics Valuation on May 29, 2024
It is possible to determine the worth of Aclaris Therapeutics on a given historical date. On May 29, 2024 Aclaris was worth 1.04 at the beginning of the trading date compared to the closed value of 1.01. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Aclaris Therapeutics stock. Still, in general, we apply an absolute valuation method to find Aclaris Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aclaris Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Aclaris Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 1.11 | 1.14 | 1.02 | 1.05 | 1,136,926 | |
05/29/2024 | 1.04 | 1.05 | 0.95 | 1.01 | 932,018 |
| 1.03 | 1.06 | 1.01 | 1.05 | 548,991 |
| Backtest Aclaris Therapeutics | | | Aclaris Therapeutics History | | | Aclaris Therapeutics Valuation | Previous | Next |
Aclaris Therapeutics Trading Date Momentum on May 29, 2024
| On May 30 2024 Aclaris Therapeutics was traded for 1.05 at the closing time. The top price for the day was 1.06 and the lowest listed price was 1.01 . The trading volume for the day was 549 K. The trading history from May 30, 2024 was a factor to the next trading day price appreciation. The overall trading delta against the next closing price was 3.96% . The overall trading delta against the current closing price is 1.98% . |
Aclaris Therapeutics Fundamentals Correlations and Trends
By evaluating Aclaris Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Aclaris financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Aclaris Therapeutics Stock history
Aclaris Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Aclaris is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Aclaris Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Aclaris Therapeutics stock prices may prove useful in developing a viable investing in Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Aclaris Therapeutics Quarterly Net Working Capital |
|
Aclaris Therapeutics Stock Technical Analysis
Aclaris Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Aclaris Therapeutics Period Price Range
Low | December 29, 2024
| High |
0.00 | 0.00 |
Aclaris Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Aclaris Therapeutics December 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Aclaris Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aclaris Therapeutics shares will generate the highest return on investment. By undertsting and applying Aclaris Therapeutics stock market strength indicators, traders can identify Aclaris Therapeutics entry and exit signals to maximize returns
Aclaris Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Aclaris Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Aclaris Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Aclaris to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1452 | |||
| Jensen Alpha | 1.82 | |||
| Total Risk Alpha | 1.53 | |||
| Sortino Ratio | 0.308 | |||
| Treynor Ratio | 111.27 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.